ARESTIN® is an antibiotic treatment placed inside infected periodontal pockets to help reduce and sometimes eliminate the infection. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg is a locally administered antibiotic (LAA) that is indicated as an adjunct therapy to scaling and root planing (SRP) procdures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program which includes good oral hygiene, and scaling and root planing. ARESTIN® Microspheres are a bioadhesive, bioresorbable polymer in powder form produced by a microencapsulation process. Once ARESTIN® is administered, it immediately adheres to the periodontal pocket. Eventually, the Microspheres themselves are fragmented through polymer hydrolysis and are completely bioresorbed
ARESTIN® maintains therapeutic drug concentrations for up to 21 days, and the localized delivery provides an effective drug concentration at the site of infection.
Periostat® is a systemically delivered collagenase inhibitor consisting of a 20-mg capsule of doxycycline hyclate for oral administration. This is the first FDA approved systemic drug for host modulation as an adjunct to scaling and root planing in the treatment of periodontitis. Periostat®, administered BID, reduced the elevated collagenase activity in the gingival fluid of patients with adult periodontitis. Study showed when SRP plus Periostat® was compared with SRP plus placebo, more sites initially demon-strating 5 to 8 mm probing depth exhibited >2 mm reduction in probing depth (41% vs. 30%, 886 vs. 640 sites). In a 3-month follow-up study, where patients received no additional therapy, pocket depth reductions and clinical attachment level gains observed following 9 months adjunctive Periostat® were maintained.